Mirtazapine provokes periodic leg movements during sleep in young healthy men

Sleep

Volumn 36, Issue 5, 2013, Pages 661-669

  Fulda, Stephany ^a   Kloiber, Stefan ^a   Dose, Tatjana ^a   Lucae, Susanne ^a   Holsboer, Florian ^a   Schaaf, Ludwig ^a   Hennings, Johannes ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Mirtazapine; Periodic leg movements; Restless legs syndrome; Sleep

Indexed keywords

MIRTAZAPINE; REMERGIL SOLTAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; ELECTROMYOGRAM; ELECTROOCULOGRAM; EPWORTH SLEEPINESS SCALE; EVENING DOSAGE; HUMAN; LEG MOVEMENT; MALE; OPEN STUDY; PERIODIC LIMB MOVEMENT DISORDER; PHYSICAL ACTIVITY; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; REM SLEEP; SLEEP; SLEEP TIME; SLEEP WAKING CYCLE;

MIRTAZAPINE; PERIODIC LEG MOVEMENTS; RESTLESS LEGS SYNDROME; SLEEP;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BODY MASS INDEX; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HEALTH STATUS; HUMANS; MALE; MIANSERIN; NOCTURNAL MYOCLONUS SYNDROME; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 84877155020     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.2622     Document Type: Article

References (91)

1. Argyropoulos S.V., Wilson SJ Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry 2005; 17: 237-45.
2. Mayers AG, Baldwin DS Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 53-59.
3. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs 2005; 65: 927-47.
4. Yang C, White DP, Winkelman JW Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58: 510-5.
5. Hoque R, Chesson AL Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med 2010; 6: 79-83.
6. Zucconi M, Ferri R, Allen R., et al The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 2006; 7: 175-83.
7. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual. 2nd ed. Westchester, Illinois: American Academy of Sleep Medicine, 2005.
8. Högl B. Periodic limb movements are associated with disturbed sleep: Pro. J Clin Sleep Med 2007; 3: 12-4.
9. Mahowald MW. Periodic limb movements are NOT associated with disturbed sleep: Con. J Clin Sleep Med 2007; 3: 15-7.
10. Gosselin N, Lanfranchi P, Michaud M., et al Age and gender effects on heart rate activation associated with periodic leg movements in patients with restless legs syndrome. Clin Neurophysiol 2003; 114: 2188-95.
11. Ferri R, Zucconi M, Rundo F., Spruyt K, Manconi M, Ferini-Strambi L. Heart rate and spectral EEG changes accompanying periodic and non-periodic leg movements during sleep. Clin Neurophysiol 2007; 118: 438-48.
12. Sforza E, Nicolas A, Lavigne G., Gosselin A, Petit D, Montplaisir J. EEG and cardiac activation during periodic leg movements in sleep: Support for a hierarchy of arousal responses. Neurology 1999; 52: 786-91.
13. Pennestri MH, Montplaisir J, Colombo R., Lavigne G, Lanfranchi PA Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology 2007; 68: 1213-18.
14. Manconi M, Ferri R, Zucconi M., et al Effects of acute dopamine-agonist treatment in restless legs syndrome on heart rate variability during sleep. Sleep Med 2011; 12: 47-55.
15. Winkelman JW. The evoked heart rate response to periodic leg movements of sleep. Sleep 1999; 22: 575-80.
16. Sforza E, Juony C, Ibanez V. Time-dependent variation in cerebral and autonomic activity during periodic leg movements in sleep: implications for arousal mechanisms. Clin Neurophysiol 2002; 113: 883-91.
17. Fantini M.L., Michaud M, Gosselin N., Lavigne G, Montplaisir J. Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activation. Neurology 2002; 59: 1889-94.
18. Lavoie S, De Bilbao F, Haba-Rubio J, Ibanez V., Sforza E. Influence of sleep stage and wakefulness on spectral EEG activity and heart rate variations around periodic leg movements. Clin Neurophysiol 2004; 115: 2236-46.
19. Ali NJ, Davies RJ, Fleetham J.A., Stradling JR Periodic movements of the legs during sleep associated with rises in systemic blood pressure. Sleep 1991; 14: 163-5.
20. Hornyak M, Feige B, Riemann D., Voderholzer U. Periodic leg movements in sleep and periodic limb movement disorder: prevalence, clinical significance and treatment. Sleep Med Rev 2006; 10: 169-77.
21. Dauvilliers Y, Pennestri M-H, Petit D, Dang-Vu T, Lavigne G., Montplai-sir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res 2007; 16: 333-9.
22. Olson EJ, Boeve BF, Silber MH Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000; 123: 331-9.
23. Ancoli-Israel S., Kripke DF, Klauber M.R., Mason WJ, Fell R, Kaplan O. Periodic limb movements in sleep in community-dwelling elderly. Sleep 1991; 14: 496-500.
24. Bixler EO, Kales A, Vela-Bueno A, Jacoby J.A., Scarone S., Soldatos CR Nocturnal myoclonus and nocturnal myoclonic activity in the normal population. Res Commun Chem Pathol Pharmacol 1982; 36: 129-40.
25. Morrish E, King MA, Pilsworth S.N., Shneerson JM, Smith IE Periodic limb movement in a community population detected by a new actigraphy technique. Sleep Med 2002; 3: 489-95.
26. Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep 2008; 31: 1221-7.
27. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010; 6: 337-46.
28. Garcia-Borreguero D., Egatz R, Winkelmann J., Berger K. Epidemiology of restless legs syndrome: the current status. Sleep Med Rev 2006; 10: 153-67.
29. Allen RP, Picchietti D, Hening W.A., Trenkwalder C., Walters AS, Montplai-sir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-19.
30. Winkelmann J, Schormair B, Lichtner P., et al Genome-wide association study of restless legs syndrome identifies common variants in three ge-nomic regions. Nat Genet 2007; 39: 1000-6.
31. Stefansson H, Rye DB, Hicks A, et al A genetic risk factor for periodic limb movements in sleep. N Engl J Med 2007; 357: 639-47.
32. Nofzinger EA, Fasiczka A, Berman S., Thase ME Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. J Clin Psychiatry 2000; 61: 858-62.
33. Salín-Pascual R.J., Galicia-Polo L, Drucker-Colín R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348-50.
34. Picchietti D, Winkelman JW Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005; 28: 891-8.
35. Rottach KG, Schaner BM, Kirch M.H., et al Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2009; 43: 70-5.
36. Wittchen H-U, Pfister H. DIA-X-Interviews: Manual für Screening-Verfahren und Interview: (a) Interviewheft Lä ngsschnittuntersuchung (DIA-X-Lifetime); (b) Ergänzungsheft (DIA-X-Lifetime); (c) Interviewheft Querschnittuntersuchung (DIA-X-12 Monate); (d) Ergänzungsheft (DIA-X-12 Monate); (e) PC-Programm zur Durchführung des Interviews (Längs- und Querschnittuntersuchung); (f) Auswertungsprogramm. (Manual). Frankfurt: Swets & Zeitlinger, 1997.
37. Buysse DJ, Reynolds CF, Monk T.H., Berman SR, Kupfer DJ The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
38. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5.
39. Horne J.A., Östberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 1976; 4: 97-110.
40. Griefahn B, Künemund C, Bröde P, Mehnert P. Zur Validität der deutschen Übersetzung des Morningness-Eveningness-Questionnaires von Horne und Östberg. Somnology 2001; 5: 71-80.
41. Fulda S, Hornyak M, Müller K, Cerny L., Beitinger P, Wetter T. Development and validation of the Munich Parasomnia Screening (MUPS). Somnology 2008; 12: 56-65.
42. Iber C, Ancoli-Israel S, Chesson A., Quan S. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. 1st ed. Westchester, IL: American Academy of Sleep Medicine, 2007.
43. Ferri R, Zucconi M, Manconi M., Plazzi G, Bruni O, Ferini-Strambi L. New approaches to the study of periodic leg movements during sleep in restless legs syndrome. Sleep 2006; 29: 759-69.
44. Ferri R, Zucconi M, Manconi M., et al Different periodicity and time structure of leg movements during sleep in narcolepsy/cataplexy and restless legs syndrome. Sleep 2006; 29: 1587-94.
45. Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25: 677-9.
46. Ruigt GS, Kemp B, Groenhout C.M., Kamphuisen HA Effect of the antide-pressant Org 3770 on human sleep. Eur J Clin Pharmacol 1990; 38: 551-4.
47. Winokur A, Sateia MJ, Hayes J.B., Bayles-Dazet W, MacDonald MM, Gary KA Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000; 48: 75-8.
48. Schmid DA, Wichniak A, Uhr M., et al Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsy-chopharmacology 2006; 31: 832-44.
49. Shen J, Chung SA, Kayumov L, et al Polysomnographic and symptoma-tological analyses of major depressive disorder patients treated with mir-tazapine. Can J Psychiatry 2006; 51: 27-34.
50. Winokur A, DeMartinis NA, McNally D.P., Gary EM, Cormier JL, Gary KA Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003; 64: 1224-9.
51. Schittecatte M, Dumont F, Machowski R., Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 2002; 46: 197-201.
52. Carley DW, Olopade C, Ruigt G.S., Radulovacki M. Efficacy of mirtazap-ine in obstructive sleep apnea syndrome. Sleep 2007; 30: 35-41.
53. Marshall NS, Yee BJ, Desai A.V., et al Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep 2008; 31: 824-31.
54. Brunner H. Success and failure of mirtazapine as alternative treatment in elderly stroke patients with sleep apnea-a preliminary open trial. Sleep Breath 2008; 12: 281-5.
55. Chang C-C, Shiah I-S, Chang H-A, Mao W-C. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Prog Neuropsychop-harmacol Biol Psychiatry 2006; 30: 316-8.
56. Pae CU, Kim T-S, Kim J-J, et al Re-administration of mirtazapine could overcome previous mirtazapine-associated restless legs syndrome? Psychiatry Clin Neurosci 2004; 58: 669-70.
57. Bahk W, Pae C, Chae J., Jun T, Kim K. Mirtazapine may have the propensity for developing a restless legs syndrome? A case report. Psychiatry Clin Neurosci 2002; 56: 209-10.
58. Aǧargün MY, Kara H, Ozbek H, Tombul T, Ozer OA. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry 2002; 63: 1179.
59. Bonin B, Vandel P, Kantelip JP Mirtazapine and restless leg syndrome: a case report. Therapie 2000; 55: 655-6.
60. Kim S-W, Shin I-S, Kim J-M, Park K-H, Youn T, Yoon J-S. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 2008; 23: 615-20.
61. Manconi M, Ferri R, Zucconi M., et al Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol 2012; 71: 834-44.
62. Ohayon MM, O'Hara R, Vitiello MV Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev 2012; 16: 283-95.
63. Sennef C, Heukels A, Van Proosdij J, Ruigt G. Effects of mirtazapine, amitriptyline and their combination on sleep in healthy volunteers measured by an ambulatory digital recording system (VITAPORT II(r)). XXIst Collegium Internationale Neuropsychopharmacologicum, Glasgow, Scotland: 12th-16th July, 1998.
64. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 2005; 6: 631-41.
65. Kraus T, Haack M, Schuld A., Hinze-Selch D, Koethe D, Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220-5.
66. Nicholas LM, Ford AL, Esposito S.M., Ekstrom RD, Golden RN The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003; 64: 883-9.
67. Radhakishun FS, Van den Bos J, Van der Heijden BC, Roes KC, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol 2000; 20: 531-7.
68. De Boer T.H., Maura G, Raiteri M., De Vos CJ, Wieringa J, Pinder RM Neurochemical and autonomic pharmacological profiles of the 6-aza-an-alogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988; 27: 399-408.
69. Sharpley AL, Elliott JM, Attenburrow M.J., Cowen PJ Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology 1994; 33: 467-71.
70. Sharpley AL, Vassallo CM, Cowen PJ Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT(2C) receptors in vivo. Biol Psychiatry 2000; 47: 468-70.
71. Beitinger M, Fulda S. Long-term effects of antidepressants on sleep. In: Pandi-Perumal SR, Kramer M, eds. Sleep and mental illness. Cambridge: Cambridge University Press, 2010: 183-210.
72. Tatsumi M, Groshan K, Blakely R.D., Richelson E. Pharmacological pro-file of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249-58.
73. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of anti-depressants. CNS Spectr 2005; 10: 732-47.
74. Guggisberg AG, Hess CW, Mathis J. The significance of the sympathetic nervous system in the pathophysiology of periodic leg movements in sleep. Sleep 2007; 30: 755-66.
75. Siddiqui F, Strus J, Ming X., Lee IA, Chokroverty S, Walters AS Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol 2007; 118: 1923-30.
76. Ware JC, Blumoff R, Pittard JT Peripheral vasoconstriction in patients with sleep related periodic leg movements. Sleep 1988; 11: 182-6.
77. Ausserwinkler M, Schmidt P. Erfolgreiche Behandlung des 'restless legs'-Syndroms bei chronischer Niereninsuffizienz mit Clonidin. Schweiz Med Wochenschr 1989; 119: 184-6.
78. Wagner ML, Walters AS, Coleman R.G., Hening WA, Grasing K, Chokroverty S. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996; 19: 52-8.
79. Zoe A, Wagner ML, Walters AS High-dose clonidine in a case of restless legs syndrome. Ann Pharmacother 1994; 28: 878-81.
80. Kugaya A, Seneca NM, Snyder P.J., et al Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepres-sant administration. Neuropsychopharmacology 2003; 28: 413-20.
81. Warwick JM, Carey PD, Cassimjee N, et al Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis 2012; 27: 151-8.
82. Pogarell O, Poepperl G, Mulert C., et al SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). European Neuropsychopharmacology 2005; 15: 521-4.
83. Nakayama K, Sakurai T, Katsu H. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull 2004; 63: 237-41.
84. Millan MJ, Gobert A, Rivet J.M., et al Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 2000; 12: 1079-95.
85. Morita M, Nakayama K. Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation. Psychiatry Clin Neurosci 2011; 65: 246-53.
86. Schreiber S, Bleich A, Pick CG Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antino-ciceptive effects-a possible opioid involvement in severe depression? J Mol Neurosci 2002; 18: 143-9.
87. Schreiber S, Rigai T, Katz Y., Pick CG The antinociceptive effect of mir-tazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull 2002; 58: 601-5.
88. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G., Roth T. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002; 22: 511-5.
89. Risberg A, Risberg J, Ingvar DH Effects of promethazine on nocturnal sleep in normal man. Psychopharmacologia 1975; 43: 279-84.
90. Almqvist M, Liljenberg B, Hetta J., Rimon R, Hambert G, Roos BE Effects of propiomazine on the EEG sleep of normal subjects. Pharmacol Toxicol 1987; 61: 278-81.
91. Allen R, Lesage S, Earley C. Anti-histamines and benzodiazepines exacerbate daytime restless legs syndrome (RLS) symptoms. Sleep 2005; 28: A279.